Table 2:
Characteristics of completely resecteda primary GISTs (PRIM) by imatinib era.
| Pre-imatinib era (n=137) | Imatinib era (n=507) | p-value | ||
|---|---|---|---|---|
| Age at first Surgery (yrs) | Median (range) | 66.6 (15.8–94.7) | 64.0 (8.1–90.1) | 0.657 |
| Sex | F | 57 (41.6) | 260 (51.3) | 0.054 |
| M | 80 (58.4) | 247 (48.7) | ||
| Primary tumor site | Stomach | 83 (60.6) | 380 (75) | 0.003 |
| Small Bowel | 29 (21.2) | 83 (16.4) | ||
| Rectum | 14 (10.2) | 28 (5.5) | ||
| Other | 11 (8) | 16 (3.2) | ||
| Primary tumor Size (cm) | <5 | 46 (33.6) | 281 (55.4) | <0.001 |
| 5–10 | 47 (34.3) | 144 (28.4) | ||
| >10 | 44 (32.1) | 82 (16.2) | ||
| Primary tumor mitotic rate per 50 HPF | ≤5 | 61 (54) | 306 (70) | 0.002 |
| >5 | 52 (46) | 131 (30) | ||
| Unknown | 24 (N/A) | 70 (N/A) | ||
| Histologic variant | Unknown | 117 (N/A) | 72 (N/A) | 0.268 |
| Epithelioid | 3 (15) | 52 (12) | ||
| Mixed | 0 (0) | 52 (12) | ||
| Spindle | 17 (85) | 331 (76.1) | ||
| Marginsa | R0 | 121 (88.3) | 476 (93.9) | 0.040 |
| R1 | 16 (11.7) | 31 (6.1) | ||
| Second malignancyb | No | 108 (78.8) | 348 (68.6) | 0.020 |
| Yes | 29 (21.2) | 159 (31.4) | ||
| Mutation | KIT exon 9 | 3 (2.9) | 10 (4.8) | c |
| KIT exon 11 deletion | 44 (42.7) | 78 (37.1) | ||
| KIT exon 11 other | 21 (20.4) | 55 (26.2) | ||
| KIT exon 13 | 0 (0) | 4 (1.9) | ||
| KIT exon 17 only | 1 (1) | 0 (0) | ||
| KIT mult exons | 1 (1) | 6 (2.9) | ||
| PDGFRA D842V/I | 3 (2.9) | 17 (8.1) | ||
| PDGFRA other | 4 (3.9) | 16 (7.6) | ||
| NF1 | 0 (0) | 4 (1.9) | ||
| SDH | 0 (0) | 0 (0) | ||
| Wild type (WT) | 26 (25.2) | 20 (9.5) | ||
| Unknown | 34 (N/A) | 297 (N/A) | ||
a
R2 margins were excluded from this analysis of disease-free survival.
b
Any preceding or synchronous second malignancy
c
There were too many categories (many with low numbers) for statistical comparison.